Free Trial

Pfizer (PFE) Competitors

Pfizer logo
$23.49 +0.20 (+0.86%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$23.54 +0.06 (+0.23%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PFE vs. AMGN, GILD, MRNA, NVAX, VTRS, ABBV, BMY, JNJ, LLY, and MRK

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), Viatris (VTRS), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Merck & Co., Inc. (MRK). These companies are all part of the "medical" sector.

Pfizer vs. Its Competitors

Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.78$4.09B$10.9627.09
Pfizer$63.63B2.10$8.03B$1.3817.02

76.5% of Amgen shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.7% of Amgen shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amgen has a net margin of 17.39% compared to Pfizer's net margin of 12.62%. Amgen's return on equity of 176.11% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen17.39% 176.11% 12.39%
Pfizer 12.62%20.33%8.53%

Amgen presently has a consensus price target of $307.27, suggesting a potential upside of 3.50%. Pfizer has a consensus price target of $28.28, suggesting a potential upside of 20.38%. Given Pfizer's stronger consensus rating and higher possible upside, analysts clearly believe Pfizer is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.35
Pfizer
1 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
3 Strong Buy rating(s)
2.50

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.3%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

In the previous week, Pfizer had 22 more articles in the media than Amgen. MarketBeat recorded 76 mentions for Pfizer and 54 mentions for Amgen. Amgen's average media sentiment score of 1.34 beat Pfizer's score of 1.02 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
43 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
49 Very Positive mention(s)
5 Positive mention(s)
11 Neutral mention(s)
8 Negative mention(s)
3 Very Negative mention(s)
Positive

Summary

Amgen beats Pfizer on 11 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFE vs. The Competition

MetricPfizerLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$133.55B$241.43B$5.52B$20.40B
Dividend Yield7.32%3.03%4.74%3.70%
P/E Ratio17.0227.1529.0529.01
Price / Sales2.104.72444.6456.95
Price / Cash5.3813.1324.4817.53
Price / Book1.5017.328.364.53
Net Income$8.03B$8.49B$3.25B$994.29M
7 Day Performance-3.45%-4.92%-3.57%-3.62%
1 Month Performance-7.68%-3.93%5.10%-2.71%
1 Year Performance-22.81%-11.43%25.36%10.16%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFE
Pfizer
4.9512 of 5 stars
$23.49
+0.9%
$28.28
+20.4%
-22.8%$133.55B$63.63B17.0281,000Trending News
Upcoming Earnings
AMGN
Amgen
4.5796 of 5 stars
$309.39
+0.1%
$307.27
-0.7%
-11.1%$166.36B$33.42B28.2328,000Positive News
Upcoming Earnings
Dividend Announcement
GILD
Gilead Sciences
4.6314 of 5 stars
$113.39
-0.1%
$111.38
-1.8%
+47.4%$141.05B$28.75B23.8717,600Positive News
Upcoming Earnings
MRNA
Moderna
4.3869 of 5 stars
$34.22
-1.3%
$46.11
+34.7%
-68.1%$13.23B$3.24B-3.925,800Trending News
Earnings Report
Analyst Forecast
Options Volume
Gap Down
NVAX
Novavax
4.5819 of 5 stars
$7.68
-2.1%
$15.86
+106.6%
-44.3%$1.24B$1.21B2.901,990Upcoming Earnings
Gap Down
VTRS
Viatris
2.1949 of 5 stars
$9.31
-0.7%
$10.40
+11.8%
-25.8%$10.92B$14.74B-2.9432,000Upcoming Earnings
Short Interest ↑
ABBV
AbbVie
4.5753 of 5 stars
$191.12
+0.3%
$211.29
+10.6%
+3.1%$337.29B$56.33B81.2655,000Trending News
Earnings Report
Analyst Forecast
Analyst Revision
BMY
Bristol Myers Squibb
4.8693 of 5 stars
$48.99
+0.0%
$58.53
+19.5%
-9.3%$99.68B$47.64B18.3534,100Trending News
Earnings Report
Analyst Forecast
Analyst Revision
JNJ
Johnson & Johnson
4.666 of 5 stars
$169.35
+0.1%
$174.50
+3.0%
+1.9%$407.29B$90.63B18.10138,100Trending News
LLY
Eli Lilly and Company
4.9136 of 5 stars
$804.53
+0.7%
$1,012.56
+25.9%
-5.3%$762.42B$49.00B65.4647,000Trending News
Upcoming Earnings
MRK
Merck & Co., Inc.
4.997 of 5 stars
$84.04
+0.1%
$108.69
+29.3%
-31.2%$210.82B$64.17B12.2275,000Trending News
Earnings Report
Analyst Revision

Related Companies and Tools


This page (NYSE:PFE) was last updated on 8/4/2025 by MarketBeat.com Staff
From Our Partners